Detalles de la búsqueda
1.
Kinetics of interferon-λ and receptor expression in response to in vitro respiratory viral infection.
Acta Virol
; 67(1): 99-108, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36950890
2.
Hybrid Proteins with Short Conformational Epitopes of the Receptor-Binding Domain of SARS-CoV-2 Spike Protein Promote Production of Virus-Neutralizing Antibodies When Used for Immunization.
Biochemistry (Mosc)
; 87(4): 319-330, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35527370
3.
Structural and Immunoreactivity Properties of the SARS-CoV-2 Spike Protein upon the Development of an Inactivated Vaccine.
Viruses
; 15(2)2023 02 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36851694
4.
SARS-CoV-2 escape from cytotoxic T cells during long-term COVID-19.
Nat Commun
; 14(1): 149, 2023 01 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36627290
5.
VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages.
J Pers Med
; 12(6)2022 May 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-35743680
6.
Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up.
EClinicalMedicine
; 50: 101526, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35770251
7.
Mass spectrometry and biochemical analysis of RNA polymerase II: targeting by protein phosphatase-1.
Mol Cell Biochem
; 347(1-2): 79-87, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-20941529
8.
Intranasal Immunization with the Influenza A Virus Encoding Truncated NS1 Protein Protects Mice from Heterologous Challenge by Restraining the Inflammatory Response in the Lungs.
Microorganisms
; 9(4)2021 Mar 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-33810549
9.
Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan.
EClinicalMedicine
; 39: 101078, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34414368
10.
5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase.
Bioorg Med Chem Lett
; 19(2): 451-8, 2009 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19054673
11.
5,5'- and 6,6'-dialkyl-5,6-dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase.
Bioorg Med Chem Lett
; 19(21): 6047-52, 2009 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19796938
12.
Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase.
Bioorg Med Chem Lett
; 19(22): 6404-12, 2009 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19818610
13.
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 2: Variation of the 2- and 6-pyridazinone substituents.
Bioorg Med Chem Lett
; 18(4): 1419-24, 2008 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18226901
14.
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 1: exploration of 7'-substitution of benzothiadiazine.
Bioorg Med Chem Lett
; 18(4): 1413-8, 2008 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18242088
15.
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents.
Bioorg Med Chem Lett
; 18(20): 5635-9, 2008 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18796353
16.
Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.
Bioorg Med Chem Lett
; 18(18): 5002-5, 2008 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18722768
17.
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties.
Bioorg Med Chem Lett
; 18(11): 3421-6, 2008 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18442904
18.
Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.
Bioorg Med Chem Lett
; 18(12): 3616-21, 2008 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18487044
19.
Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymerase.
Bioorg Med Chem Lett
; 18(14): 4181-5, 2008 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18554907
20.
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments.
Bioorg Med Chem Lett
; 18(11): 3446-55, 2008 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18457949